It will be important to understand the heterogeneity and mutational evolution of breast tumors initiated by somatic p53 mutations, which may enable tailoring of therapeutic strategies to the fundamental molecular lesions driving a particular tumor. This evidence concerns the gene TP53 and breast neoplasm.